Evidence map›Paper›PMID 39496579›Full record

ArticleInfluenza and other respiratory viruses2024

Trends in COVID-19-Attributable Hospitalizations Among Adults With Laboratory-Confirmed SARS-CoV-2-COVID-NET, June 2020 to September 2023.

Christopher A Taylor, Michael Whitaker, Monica E Patton, Michael Melgar, Pam Daily Kirley, Breanna Kawasaki, Kimberly Yousey-Hindes, Kyle P Openo, Patricia A Ryan, Sue Kim and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Christopher A TaylorNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-0937-5461
Michael WhitakerNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Monica E PattonNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Michael MelgarNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-3243-9854
Pam Daily KirleyCalifornia Emerging Infections Program, Oakland, California, USA.
Breanna KawasakiColorado Department of Public Health & Environment, Denver, Colorado, USA.
Kimberly Yousey-HindesConnecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA.
Kyle P OpenoEmory University School of Medicine, Atlanta, Georgia, USA.
Patricia A RyanMaryland Department of Health, Baltimore, Maryland, USA.
Sue KimMichigan Department of Health and Human Services, Lansing, Michigan, USA.
Kathryn Como-SabettiMinnesota Department of Health, St. Paul, Minnesota, USA.
Dominic SolhtalabNew Mexico Emerging Infections Program, Albuquerque, New Mexico, USA.
Grant BarneyNew York State Department of Health, Albany, New York, USA.
Brenda L TesiniUniversity of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Nancy E MoranOhio Department of Health, Columbus, Ohio, USA.
Melissa SuttonPublic Health Division, Oregon Health Authority, Portland, Oregon, USA.
H Keipp TalbotVanderbilt University Medical Center, Nashville, Tennessee, USA.
Kristen OlsenSalt Lake County Health Department, Salt Lake City, Utah, USA.
Fiona P HaversNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

CDC HHS CK17-1701CDC HHS CK24-2401CDC HHS NU38OT000297CDC HHS NU38OT000297-02-00
6 · The paper itself

Abstract

backgroundScreening for SARS-CoV-2 infection among hospital admissions made interpretation of COVID-19 hospitalization data challenging as SARS-CoV-2-positive persons with mild or asymptomatic infection may be incorrectly identified as COVID-19-associated hospitalizations. The study objective is to estimate the proportion of hospitalizations likely attributable to COVID-19 among SARS-CoV-2-positive hospitalized patients.

methodsA sample of laboratory-confirmed SARS-CoV-2-positive hospitalizations from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) from June 2020 to September 2023 was analyzed, with a focus on July 2022 to September 2023. Likely COVID-19-attributable hospitalizations were defined as hospitalizations among SARS-CoV-2-positive non-pregnant adults ages ≥ 18 years with COVID-19-related presenting complaint, treatment, or discharge diagnosis.

resultsAmong 44,816 sampled hospitalizations, 90% met the definition of likely COVID-19-attributable. Among the 9866 admissions occurring during July 2022 to September 2023, 86% were likely COVID-19-attributable; 87% had a COVID-19-related presenting complaint, 64% received steroids or COVID-19-related treatment, 47% had respiratory- and 10% had coagulopathy-related discharge diagnoses, and 39% had COVID-19 as the principal discharge diagnosis code. More than 70% met ≥ 2 criteria. Compared with likely COVID-19-attributable hospitalizations, SARS-CoV-2-positive patients who did not meet the case definition were more likely to be ages 18-49 years (27% vs. 13%), have no underlying medical conditions (14% vs. 4%), or be asymptomatic for COVID-19 upon admission (46% vs. 10%) (all p < 0.05).

conclusionsMost hospitalizations among SARS-CoV-2-positive adults in a recent period were likely attributable to COVID-19. COVID-19-attributable hospitalizations are less common among younger SARS-CoV-2-positive hospitalized adults but still account for nearly three quarters of all admissions among SARS-CoV-2-positive adults in this age group.

Indexed as

COVID-19HospitalizationSARS-CoV-2AdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedUnited StatesYoung AdultCOVID‐19epidemiologyhospitalizationspopulation‐based surveillance

Identifiers

PMID39496579
PMCPMC11534501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.